A 49-year-old man presented to the clinic reporting fever, night sweats, palpitations,
and shortness of breath. He had been experiencing symptoms for the past 6 weeks, starting
with severe fatigue after a usual 7-mile run, followed by 2 weeks of intermittent
fever and 4 weeks of dry cough and night sweats. During this time, he experienced
10-lb weight loss and physical activity was limited by shortness of breath; he was
also experiencing intermittent palpitations. At baseline he was able to run up to
15 miles, but experienced substantial loss of exercise tolerance and was no longer
able to sustain prolonged running. He had been seen by his primary care physician
and diagnosed with recurrent episodes of bronchitis. With multiple rounds of empirical
oral antibiotics, most recently azithromycin approximately 3 weeks before his presentation,
his symptoms improved after each course followed by a relapse.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.Am J Respir Crit Care Med. 2012; 185: 435-452https://doi.org/10.1164/rccm.201111-2042ST
- American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for Healthcare Professionals From the American Heart Association.Circulation. 2015; 132 (Published corrections appear in Circulation. 2015;132(17):e215, Circulation. 2016;134(8):e113, and Circulation. 2018;138(5):e78-e79. https://doi.org/10.1161/CIR.0000000000000296): 1435-1486
- Native-valve infective endocarditis.N Engl J Med. 2020; 383: 567-576https://doi.org/10.1056/NEJMcp2000400
- HACEK endocarditis: a review.Expert Rev Anti Infect Ther. 2016; 14: 539-545https://doi.org/10.1080/14787210.2016.1184085
- ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation. 2014; 129 (Published correction appears in Circulation. 2014;129(23):e650. https://doi.org/10.1161/CIR.0000000000000029): 2440-2492
- American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.Circulation. 2007; 116 (Published correction appears in Circulation. 2007;116(15):e376-e377. https://doi.org/10.1161/CIRCULATIONAHA.106.183095): 1736-1754
- Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.Clin Infect Dis. 2000; 30: 633-638https://doi.org/10.1086/313753
- Diagnosis and genotyping of Coxiella burnetii endocarditis in a patient with prosthetic pulmonary valve replacement using next-generation sequencing of plasma microbial cell-free DNA.Open Forum Infect Dis. 2019; 6: ofz242https://doi.org/10.1093/ofid/ofz242
- Characteristic morphologies of the bicuspid aortic valve in patients with genetic syndromes.J Am Soc Echocardiogr. 2018; 31: 194-200https://doi.org/10.1016/j.echo.2017.10.008
- Ascending aortic dilatation associated with bicuspid aortic valve pathophysiology, molecular biology, and clinical implications.Circulation. 2009; 119: 880-890https://doi.org/10.1161/CIRCULATIONAHA.108.795401
- BAVCon Investigators. Bicuspid aortic valve identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon).Circulation. 2014; 129: 2691-2704https://doi.org/10.1161/CIRCULATIONAHA.113.007851
- Contemporary natural history of bicuspid aortic valve disease: a systematic review.Heart. 2017; 103: 1323-1330https://doi.org/10.1136/heartjnl-2016-309916
CORRECT ANSWERS: 1. d. 2. c. 3. c. 4. e. 5. b
Article info
Footnotes
See end of article for correct answers to questions.
Identification
Copyright
© 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
